Drug intelligence / Profile preview

V0474

Development stage: Unknown
Lead developer: Pierre Fabre
Modality: Small Molecules
Administration: Oral

Overview

V0474 is a new nicotine lozenge formulation developed by Pierre Fabre Medicament. It is being investigated in a pilot pharmacokinetic study to assess its pharmacokinetic profile, clinical and biological safety, and acceptability following single oral administration in healthy male smokers. The drug is intended for nicotine replacement therapy, delivering nicotine through a lozenge formulation.

Other names: Nicotine lozenge V0474B-Pierre Fabre Medicament-tobacco use disorder

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on V0474.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V0474.

Explore the full profile